Drug Research
Thermo Fisher Launches Adolescent Alopecia Areata Registry
Thermo Fisher Scientific Inc., the global leader in serving science, has announced the launch of the international CorEvitas Adolescent Alopecia Areata (AA) Registry. This initiative addresses a significant unmet need for real-world, adolescent-specific data on alopecia areata, an autoimmune...
BioPharma
Thermo Fisher Partners with X-ELIO for Renewable Energy
Thermo Fisher Scientific has taken a significant step toward achieving its sustainability goals by signing a 10-year virtual power purchase agreement (VPPA) with renewable energy developer X-ELIO. This agreement supports the Lorca solar project, which is set to become...
Clinical Trials
New Data Shows Gazyva’s Superiority in Lupus Nephritis
The New England Journal of Medicine has published detailed findings from Roche’s Phase III REGENCY trial, which demonstrated the superiority of Gazyva®/Gazyvaro® (obinutuzumab) in combination with standard therapy for treating active lupus nephritis (LN). The trial shows a compelling...
Drug Research
FDA Approves Roche’s Susvimo for Diabetic Macular Edema
Roche has announced that the U.S. Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL as the first and only continuous delivery treatment for diabetic macular edema (DME), a leading cause of vision loss in adults...
Clinical Trials
EYLEA HD® Phase 3 Trial Yields Promising Results
Regeneron Pharmaceuticals, Inc. announced promising results from the Phase 3 QUASAR trial investigating EYLEA HD® (aflibercept) Injection 8 mg for treating macular edema in patients with retinal vein occlusion (RVO). The results were presented during the Angiogenesis 2025 annual...
Clinical Trials
Pfizer’s BRAFTOVI Improves Survival in Phase 3 Trial
Pfizer has announced groundbreaking results from the Phase 3 BREAKWATER trial, showcasing the effectiveness of its BRAFTOVI® (encorafenib) combination regimen in the treatment of metastatic colorectal cancer (mCRC) with the BRAF V600E mutation. The trial highlights significant improvements in...
Press Releases
FlyPharma 2025 Amsterdam officially announced as contracts are signed with host sponsors
FlyPharma, the leading platform for the pharmaceutical logistics and supply chain industry, is thrilled to announce its ninth European conference, which will take place in Amsterdam from October 8-9, 2025. The FlyPharma Amsterdam 2025 conference will convene industry experts to explore...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
